New combo attack on tough blood cancer shows promise in early trial
NCT ID NCT07093710
First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 16 times
Summary
This study tests two new drug combinations for people with peripheral T-cell lymphoma (a rare blood cancer) that has returned or not improved after standard treatment. About 101 participants will receive either golidocitinib plus mitoxantrone liposome or golidocitinib plus chidamide. The goal is to see if these combos can shrink tumors safely and find the best doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.